Antibodies against PDGFRa
US8128929B2 · kind B2 · utility
8Cited by
48References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 19, 2006 |
| Grant date | Mar 6, 2012 |
| Priority date | — |
| Expiry date | Dec 20, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides methods for neutralizing activation of PDGFRα and methods of treating a mammal with a neoplastic disease using the antibodies alone or in combination with other agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.